| Rank | Title | Journal | Year | PubWeight™‹?› |
|---|---|---|---|---|
| 1 | GSK1120212 (JTP-74057) is an inhibitor of MEK activity and activation with favorable pharmacokinetic properties for sustained in vivo pathway inhibition. | Clin Cancer Res | 2011 | 3.36 |
| 2 | Novel mechanism of lapatinib resistance in HER2-positive breast tumor cells: activation of AXL. | Cancer Res | 2009 | 3.10 |
| 3 | Smyd3 regulates cancer cell phenotypes and catalyzes histone H4 lysine 5 methylation. | Epigenetics | 2012 | 1.19 |